Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ambrx Biopharma (AMAM)
NASDAQ:AMAM
Ambrx Biopharma (AMAM) Stock Price & Analysis
207 Followers
AMAM Stock Chart & Stats
Day’s Range$27.98 - $28
52-Week Range― - ―
Previous Close$27.98
Volume1.44M
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$28.00Price Target Upside0.00%
Rating ConsensusHold
Number of Analyst Covering5
Ambrx Biopharma News
PremiumCompany Announcements
Ambrx Biopharma’s Landmark Merger and Corporate Overhaul
PremiumCompany Announcements
Ambrx Biopharma: Vote Results and Forward-Looking Statements Warning
PremiumCompany Announcements
Ambrx Biopharma Nears Acquisition by Johnson & Johnson
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
AMAM FAQ
What was Ambrx Biopharma’s price range in the past 12 months?
Currently, no data Available
What is Ambrx Biopharma’s market cap?
Currently, no data Available
When is Ambrx Biopharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Ambrx Biopharma’s earnings last quarter?
Currently, no data Available
Is Ambrx Biopharma overvalued?
According to Wall Street analysts Ambrx Biopharma’s price is currently same.
Does Ambrx Biopharma pay dividends?
Ambrx Biopharma does not currently pay dividends.
What is Ambrx Biopharma’s EPS estimate?
Ambrx Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ambrx Biopharma have?
Currently, no data Available
What happened to Ambrx Biopharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Ambrx Biopharma?
Among the largest hedge funds holding Ambrx Biopharma’s share is Woodline Partners LP. It holds Ambrx Biopharma’s shares valued at 18M.
---
Ambrx Biopharma Stock Smart Score
Company Description
Ambrx Biopharma
Ambrx Biopharma Inc is a clinical-stage biologics company focused on discovering and developing a novel class of engineered precision biologics (EPBs) using its proprietary expanded genetic code technology platform that allows incorporating synthetic amino acids (SAAs) into proteins within living cells. Its product pipeline includes ARX788, ARX517, ARX305 among others.
---
AMAM Stock 12 Months Forecast
Average Price Target
$28.00
▲(0.00% Upside)
Technical Analysis
Best Analysts Covering AMAM
1 Year
1 Year Success Rate
3/3 ratings generated profit
1 Year Average Return
+136.53%
reiterated a buy rating 6 months ago
Copying Matthew Biegler's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +136.53% per trade.
---